Francesco Ardesi

Dr. Francesco Ardesi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
MVMarco Vanetti
Marco Vanetti
Dina ViscaDina Visca
Dina Visca
FAFrancesco Ardesi
Francesco Ardesi
MZMartina Zappa
Martina Zappa
PPPatrizia Pignatti
Patrizia Pignatti
ASAntonio Spanevello
Antonio Spanevello
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterised by chronic respiratory symptoms, fixed airway obstruction and persistent inflammation that leads to a progressive airflow limitation. Although COPD has traditionally been linked to neutrophilic inflammation, recent studies have identified a subset of patients – approximately 20%–40% – with elevated eosinophil levels in blood and sputum. Emerging evidence suggests that eosinophilic inflammation has a pivotal role in a subset of COPD patients and may influence disease progression, exacerbation frequency and therapeutic responses. This narrative review provides a comprehensive analysis of the role of eosinophils in COPD with particular attention to their role as biomarkers in blood and sputum. We evaluate the prevalence of eosinophilic inflammation in COPD exanimating different thresholds used in blood and in sputum to define it. In addition, we focus on eosinophilic COPD phenotype as a treatable trait, emphasising recent evidence that supports the effectiveness of biological target therapy.

27 February 2025 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
Dina ViscaDina Visca
Dina Visca
FAFrancesco Ardesi
Francesco Ardesi
MZMartina Zappa
Martina Zappa
PPPatrizia Pignatti
Patrizia Pignatti
RCRosella Centis
Rosella Centis
ASAntonio Spanevello
Antonio Spanevello
Extract Asthma is a heterogeneous disease, generally characterised by chronic inflammation of the airways. Phenotyping has recently become a core tool to optimise its management and treatment [1] and biomarkers identification is now even more crucial. Blood eosinophils count is the most widely available inflammatory biomarker used for both therapeutic guidance and monitoring treatment response. Induced sputum (IS) is the gold-standard for a non-invasive assessment of airway inflammatory cell distribution. Four patterns have been identified based on the percentage of eosinophils and neutrophils in IS: eosinophilic, neutrophilic, mixed granulocytic and pauci-granulocytic [2].

17 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Dina ViscaDina Visca
Dina Visca
FAFrancesco Ardesi
Francesco Ardesi
RCRosella Centis
Rosella Centis
PPPatrizia Pignatti
Patrizia Pignatti
ASAntonio Spanevello
Antonio Spanevello
(1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to modern clinical practice, thus acquiring fresh relevance and meaning. (2) Methods: A non-systematic search of the literature was conducted using both MeSH and free-text phrases. No limitations on the research design or type of publication were applied. (3) Results: Reliable data regarding “Brittle Asthma” are lacking due to the paucity of current data and the few studies available. After a few years of reworking, it was divided into two sub-classes: one characterized by a wide PEF variability despite high-dose therapy and the other by sudden acute attacks in otherwise apparently normal airway functions or well-controlled asthma. Their characteristics were hardly defined because of their low prevalence. Data regarding risk factors, atopy, mechanisms, and treatments were analyzed. (4) Conclusions: Over time, different terminology has been introduced to define asthma severity and control. It would be worth investigating whether the term “Brittle Asthma” previously used may be helpful to find new hints to stratify patients and improve disease management.

24 March 2025 in ERJ Open Research
Verified
Journal Article
Open access
CLClarice X. Lim
Clarice X. Lim
RAReshed Abohalaka
Reshed Abohalaka
RWRan Wang
Ran Wang
DSDominic L. Sykes
Dominic L. Sykes
FAFrancesco Ardesi
Francesco Ardesi
ABAugusta Beech
Augusta Beech
This article presents highlights from #ERSCongress 2024 from Assembly 5 (airway diseases, asthma, COPD and chronic cough) https://bit.ly/4070nNw.

1 October 2026 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
FAFrancesco Ardesi
Francesco Ardesi
MVMarco Vanetti
Marco Vanetti
FFFederico Fassio
Federico Fassio
RCRosella Centis
Rosella Centis
MZMartina Zappa
Martina Zappa
Dina ViscaDina Visca
Dina Visca
Extract The management of severe asthma has been redefined by targeted biologic therapies [1], changing not only patient outcomes but also the way treatment success is conceptualized and measured [2]. Traditional frameworks categorized clinical benefit from non-response to response, mainly based on exacerbation reduction and oral corticosteroid (OCS) sparing [3, 4]. Recently, remission has emerged as a more ambitious treatment goal, integrating absence of exacerbations and OCS use with adequate symptom control and preserved or stable lung function [5, 6].

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
FAFrancesco Ardesi
Francesco Ardesi
MZMartina Zappa
Martina Zappa
PPPatrizia Pignatti
Patrizia Pignatti
SGSarah Grossi
Sarah Grossi
RCRosella Centis
Rosella Centis
ASAntonio Spanevello
Antonio Spanevello
Background: Anti-IL5 receptor α is used to reduce the number of exacerbations and improve disease control in T2 severe asthma patients. Aims and Objectives: To evaluate the effects of anti-IL5 receptor α on systemic and airway inflammation, disease control, lung function in real life T2 severe asthmatic patients after 12-month treatment. Methods: A retrospective study has been conducted in our severe asthma centre. A comparison of clinical, functional, and inflammatory (induced sputum eosinophils-SE and blood eosinophils-BE) characteristics were assessed at baseline (T0) and after 12 months of treatment (T12). Results: 17 patients [median (IQR) age 56 (48.5-61.5) years; 6 (35.3%) males] with severe asthma were enrolled. At T12 after anti IL-5 receptor α treatment, a significant improvement in FEV1% [median (IQR) (79 (59-101.5) to 93 (79.8-104.0); p=0.006] and FEF 25-75% [median (IQR) 55.0 (32.5-85.5) to 88 (49-104); p=0.036] was observed, with a normalization of the Tiffenau index [median (IQR) 67.8 (57.0-76.7) to 77.1 (67.1-81.1); p=0.011)]. A significant reduction of exacerbations (p=0.001), OCS dose (p=0.005) and Asthma Control Test score was observed (p=0.001). The ability of sputum production was significantly reduced (p=0.031) as well as SE% [median (IQR) 57.1 (13.0-79.9) to 0 (0-0.3); (p=0.018)] and BE count [median (IQR) 620 (270.8-845.7) to 0 (0-0); (p<0.001)] and BE% (p<0.001). Conclusions: After 12 months of treatment with anti-IL-5 receptor α, improvement of FEV1% and FEF 25-75%, normalization of Tiffenau index and increase of disease control were accompanied by a significant decrease in the rate of expectoration ability and by a substantial reduction in both systemic and airway eosinophilic inflammation.